The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Monoclonal antibody 'nirsevimab' highly effective in preventing severe RSV in infants, reducing hospitalisations and ICU ...

The monoclonal antibody nirsevimab, designed to mimic natural antibodies, significantly reduces severe RSV-related ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the antibody 'nirsevimab' reduces risk of RSV-related hospitalisations by 83 ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the antibody 'nirsevimab' reduces risk of RSV-related hospitalisations by 83 ...